ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Issues Warning Letter to Alkermes americanpharmaceuticalreview
December 19, 2019The U.S. Food and Drug Administration (FDA) posted a warning letter to Alkermes of Massachusetts, for misbranding the drug Vivitrol (an extended-release injection formulation ... -
FDA issues warning letter for misrepresentation of drug in advertisement europeanpharmaceuticalreview
December 16, 2019Alkermes, Inc. have received the warning letter after a promotional material review found it failed to adequately represent the risks of using the drug Vivitrol for patients with opioid use disorder.
Pharma Sources Insight January 2025
